Related Experiment Video

Updated: May 1, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.0K

MicroRNAs and drug resistance in prostate cancers

Feng Li1, Ram I Mahato

  • 1Department of Pharmaceutical Sciences, School of Pharmacy, Hampton University , Hampton, Virginia 23668, United States.

Molecular Pharmaceutics
|April 19, 2014
PubMed

Insights

MicroRNAs (miRNAs) play a crucial role in the development of drug-resistant prostate cancer by influencing key mechanisms like androgen signaling and apoptosis. Targeting specific miRNAs offers promising therapeutic strategies for overcoming treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer is a leading cause of cancer death in men, often treated with androgen deprivation therapy (ADT).
  • Prostate cancers can become resistant to ADT and standard chemotherapies like taxanes.
  • MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression and are implicated in cancer progression and drug resistance.

Purpose of the Study:

  • To discuss the roles of miRNAs in the development of resistant prostate cancers.
  • To explore how miRNAs contribute to various drug resistance mechanisms.
  • To review therapeutic strategies targeting miRNAs for resistant prostate cancer treatment.

Main Methods:

  • Literature review and synthesis of current research on miRNAs in prostate cancer.
  • Analysis of miRNA involvement in androgen signaling, apoptosis, multidrug resistance (MDR), epithelial-mesenchymal transition (EMT), and cancer stem cells (CSCs).
  • Discussion of miRNA-based therapeutic strategies and delivery methods.

Main Results:

  • Aberrant miRNA expression is linked to the development of resistant prostate cancers.
  • miRNAs influence multiple drug resistance mechanisms, including altered androgen signaling, apoptosis evasion, MDR transporters, EMT, and CSCs.
  • Targeting specific miRNAs and employing novel delivery strategies show potential for treating resistant prostate cancers.

Conclusions:

  • miRNAs are critical regulators in the progression of prostate cancer to a drug-resistant state.
  • Understanding miRNA functions provides a basis for developing novel therapeutic approaches to overcome chemoresistance.
  • Targeting miRNAs represents a promising avenue for future prostate cancer treatment strategies, with ongoing clinical investigations into delivery methods.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.3K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

5.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K